A Phase 4 interventional study of liraglutide and metformin in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 41 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-24.
Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 33rd largest by enrollment, is one of 13 that started in 2014, is one of 48 in phase 4, and was the 80th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 13 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 343 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 155th largest by enrollment of the 428 interventional ones that give a count, is one of 22 that started in 2014, is one of 75 in phase 4, and was the 353rd registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa and Asia. The aim of the trial is to investigate the efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with metformin during Ramadan in subjects with type 2 diabetes (T2DM).
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 343 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liraglutide 1.8 mg administered once daily subcutaneously, in combination with pre-trial tablet metformin of unchanged dose.
Drug: liraglutide · Drug: metformin
Subjects continued on pre-trial sulphonylurea tablet treatment, in combination with pre-trial tablet metformin of unchanged dose.
Drug: metformin · Drug: sulphonylurea
1.8 mg administered subcutaneously (s.c., under the skin) once daily
Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
Change in Fructosamine From Start of Ramadan to End of Ramadan
The level of fructosamine in the blood was used to assess the glycaemic control in the patients during the time period described- from start of Ramadan (day -1, visit 8) to end of Ramadan (day 29, visit 12).
Time frame: Day -1, day 29
Fructosamine at End of Ramadan
The fructosamine values at the end of Ramadan (visit 12) were presented
Time frame: Day 29
Change From Start of Ramadan to End of Ramadan in Fasting Plasma Glucose (FPG)
The level of FPG in the blood of fasting patients was addressed to monitor glycaemic control during the period described.
Time frame: Day -1, day 29
Change From Baseline to End of Ramadan in Fasting Plasma Glucose
The changes from baseline measured postbaseline (i.e., the changes measured on visit 8 and 12) entered as the dependent variables, and visit, treatment, country, and the stratification variables were included as fixed factors and the corresponding values for the specific endpoint measured at randomisation as covariate.
Time frame: Baseline, day 29
Change From Baseline to End of Ramadan in Glycosylated Haemoglobin (HbA1c)
The level of glycosylated haemoglobin in blood was used to assess the glycaemic control of the patients during the time period described.
Time frame: Baseline, day 29
Change From Baseline to End of Ramadan in Body Weight
Time frame: Baseline, day 29
Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol) (ADA Target)
Subjects who at end of treatment (Visit 14, 4 weeks post Ramadan) achieve (y/n): HbA1c below 7.0% (53 mmol/mol) (ADA target)
Time frame: Visit 14 (4 weeks post Ramadan)
Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol), and no Confirmed Hypoglycaemic Episodes
Subjects who at end of treatment (Visit 14, 4 weeks post Ramadan) achieve (y/n): HbA1c below 7.0% (53 mmol/mol) (ADA target)
Time frame: Visit 14 (4 weeks post Ramadan)
Number of Confirmed Hypoglycaemic Episodes During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.
Time frame: Day -1 to day 29
Number of Treatment Emergent Adverse Events (TEAEs) During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period.
A serious AE was an experience that at any dose resulted in any of the following: Death, a life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, a persistent or significant disability or incapacity, congenital anomaly or birth defect, important medical events. Mild - no or transient symptoms, no interference with the subject's daily activities Moderate - marked symptoms, moderate interference with the subject's daily activities Severe - considerable interference with the subject's daily activities, unacceptable
Time frame: Day -1 to day 29
The trial was conducted at 39 sites in 7 countries as follows: Algeria: 7 sites; Israel: 4 sites; India: 5 sites; Lebanon: 2 sites; Malaysia: 7 sites; South Africa: 8 sites; United Arab Emirates: 6 sites
| Milestone | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| Started | 172 | 171 |
| Exposed | 171 | 170 |
| Exposed during ramadan (fasting) | 152 | 163 |
| Completed | 146 | 147 |
| Not completed | 26 | 24 |
| Withdrew: Adverse event | 11 | 0 |
| Withdrew: Withdrawal criteria | 8 | 14 |
| Withdrew: Unclassified | 0 | 3 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Lost to follow-up | 3 | 4 |
The level of fructosamine in the blood was used to assess the glycaemic control in the patients during the time period described- from start of Ramadan (day -1, visit 8) to end of Ramadan (day 29, visit 12).
| umol/L | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| Change in Fructosamine From Start of Ramadan to End of Ramadan | -13.2 ± 36.0 | -14.9 ± 43.0 |
The fructosamine values at the end of Ramadan (visit 12) were presented
| umol/L | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| Fructosamine at End of Ramadan | 276.8 ± 44.1 | 284.9 ± 46.6 |
The level of FPG in the blood of fasting patients was addressed to monitor glycaemic control during the period described.
| mmol/L | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| Change From Start of Ramadan to End of Ramadan in Fasting Plasma Glucose (FPG) | -0.1 ± 2.0 | 0.1 ± 3.8 |
The changes from baseline measured postbaseline (i.e., the changes measured on visit 8 and 12) entered as the dependent variables, and visit, treatment, country, and the stratification variables were included as fixed factors and the corresponding values for the specific endpoint measured at randomisation as covariate.
| mmol/L | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| Change From Baseline to End of Ramadan in Fasting Plasma Glucose | -1.8 ± 3.1 | -0.6 ± 3.6 |
The level of glycosylated haemoglobin in blood was used to assess the glycaemic control of the patients during the time period described.
| Percent (%) glycosylated haemoglobin | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| Change From Baseline to End of Ramadan in Glycosylated Haemoglobin (HbA1c) | -1.3 ± 1.1 | -0.7 ± 0.9 |
| kg | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| Change From Baseline to End of Ramadan in Body Weight | -5.40 ± 0.2205 | -1.46 ± 0.2139 |
Subjects who at end of treatment (Visit 14, 4 weeks post Ramadan) achieve (y/n): HbA1c below 7.0% (53 mmol/mol) (ADA target)
| percentage (%) of subjects | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol) (ADA Target) | 51.0 | 29.9 |
Subjects who at end of treatment (Visit 14, 4 weeks post Ramadan) achieve (y/n): HbA1c below 7.0% (53 mmol/mol) (ADA target)
| percentage (%) of subjects | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| Subjects Who at End of Treatment (4 Weeks Post Ramadan) Achieve (y/n): HbA1c Below 7.0% (53 mmol/Mol), and no Confirmed Hypoglycaemic Episodes | 47.6 | 25.2 |
| Events/1000 years of patient exposure | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| Number of Confirmed Hypoglycaemic Episodes During Ramadan (Fasting), Based on Each Subject's Individual Fasting Period. | 246 | 623 |
A serious AE was an experience that at any dose resulted in any of the following: Death, a life-threatening experience, in-patient hospitalisation or prolongation of existing hospitalisation, a persistent or significant disability or incapacity, congenital anomaly or birth defect, important medical events. Mild - no or transient symptoms, no interference with the subject's daily activities Moderate - marked symptoms, moderate interference with the subject's daily activities Severe - considerable interference with the subject's daily activities, unacceptable
| Events/1000 years of patient exposure | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| Adverse events | 5258 | 3349 |
| Serious adverse events | 164 | 0 |
| Severe adverse events | 411 | 78 |
| Moderate adverse event | 986 | 779 |
| Mild adverse event | 3861 | 2492 |
Collected over A treatment emergent AE during Ramadan (fasting) had onset on or after the individual subject's first day of Ramadan fasting, and no later than the individual subject's last day of Ramadan fasting.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide and Metformin | — | 2/152 (1.3%) | 8/152 (5.3%) |
| Sulfonylurea and Metformin | — | 0/163 (0%) | 1/163 (0.6%) |
| Event | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| Abscess limbInfections and infestations | 1/152 | 0/163 |
| GastroenteritisInfections and infestations | 1/152 | 0/163 |
| Event | Liraglutide and Metformin | Sulfonylurea and Metformin |
|---|---|---|
| VomitingGastrointestinal disorders | 8/152 | 1/163 |
Safety analysis set
| Age, Continuous(years) | Liraglutide and Metformin | Sulfonylurea and Metformin | Total |
|---|---|---|---|
| Mean | 54.9 ± 9.27 | 54.0 ± 9.33 | 54.5 ± 9.30 |
| Sex: Female, Male(Participants) | Liraglutide and Metformin | Sulfonylurea and Metformin | Total |
|---|---|---|---|
| Female | 86 | 87 | 173 |
| Male | 85 | 83 | 168 |
Ran from Jan 2014 to primary completion in Sep 2014, 7 months.
Results were first posted in Oct 2015, 1 year 1 month after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 7 months is below that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide